Literature DB >> 2338443

Determination of navelbine and desacetylnavelbine in biological fluids by high-performance liquid chromatography.

F Jehl1, J Debs, C Herlin, E Quoix, C Gallion, H Monteil.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2338443     DOI: 10.1016/s0378-4347(00)83397-6

Source DB:  PubMed          Journal:  J Chromatogr


× No keyword cloud information.
  8 in total

Review 1.  Clinical pharmacokinetics of vinorelbine.

Authors:  D Levêque; F Jehl
Journal:  Clin Pharmacokinet       Date:  1996-09       Impact factor: 6.447

2.  Clinical phase I and pharmacokinetic trial of vinorelbine administered as single intravenous bolus every 21 days in cancer patients.

Authors:  T Schilling; H H Fiebig; S Kerpel-Fronius; B Winterhalter; P Variol; P Tresca; B Heinrich; A R Hanauske
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

Review 3.  Vinorelbine. A review of its pharmacological properties and clinical use in cancer chemotherapy.

Authors:  K L Goa; D Faulds
Journal:  Drugs Aging       Date:  1994-09       Impact factor: 3.923

Review 4.  Preclinical and clinical pharmacology of vinca alkaloids.

Authors:  X J Zhou; R Rahmani
Journal:  Drugs       Date:  1992       Impact factor: 9.546

5.  Biliary elimination and pharmacokinetics of vinorelbine in micropigs.

Authors:  D Levêque; M Merle-Melet; L Bresler; J P Didelot; J P Aymard; J Wihlm; F Jehl
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

6.  A new lipid-based nano formulation of vinorelbine.

Authors:  Fatemeh Bahadori; Gülaçtı Topçu; Mehmet S Eroğlu; Hayat Onyüksel
Journal:  AAPS PharmSciTech       Date:  2014-05-29       Impact factor: 3.246

7.  Pulmonary distribution of vinorelbine in patients with non-small-cell lung cancer.

Authors:  D Levêque; E Quoix; P Dumont; G Massard; J G Hentz; A Charloux; F Jehl
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 8.  Vinorelbine--a clinical review.

Authors:  R K Gregory; I E Smith
Journal:  Br J Cancer       Date:  2000-06       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.